{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:58:03Z","timestamp":1790301483515,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamaoncol.2020.4643","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T11:02:17Z","timestamp":1602759737000},"page":"1931","source":"Crossref","is-referenced-by-count":114,"title":["Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site"],"prefix":"10.1001","volume":"6","author":[{"given":"Hidetoshi","family":"Hayashi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology\/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Akiyoshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Segawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, International Medical Center, Saitama Medical University, Hidaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ueda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hiroshima City Hospital Organization, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kondoh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Sawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Chiba","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Kindai University Hospital, Osaka-Sayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Togashi","sequence":"additional","affiliation":[{"name":"Chiba Cancer Center, Research Institute, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuta","family":"Tomida","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9824","key":"coi200076r1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site.","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"coi200076r2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMra1303917","article-title":"Cancer of unknown primary site.","volume":"371","author":"Varadhachary","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"coi200076r3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrclinonc.2011.158","article-title":"Carcinomas of an unknown primary origin\u2014diagnosis and treatment.","volume":"8","author":"Massard","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"coi200076r4","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-020-0359-1","article-title":"Progress in refining the clinical management of cancer of unknown primary in the molecular era.","author":"Rassy","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"coi200076r5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1023\/A:1008369812295","article-title":"Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.","volume":"11","author":"Greco","year":"2000","journal-title":"Ann Oncol"},{"issue":"17","key":"coi200076r6","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2000.18.17.3101","article-title":"Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.","volume":"18","author":"Briasoulis","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi200076r7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/j.seminoncol.2008.10.005","article-title":"Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors.","volume":"36","author":"Greco","year":"2009","journal-title":"Semin Oncol"},{"issue":"3","key":"coi200076r8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jare.2014.11.007","article-title":"A mini review on cancer of unknown primary site: a clinical puzzle for the oncologists.","volume":"6","author":"Pavlidis","year":"2015","journal-title":"J Adv Res"},{"issue":"7","key":"coi200076r9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ctrv.2013.03.001","article-title":"Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature.","volume":"39","author":"Petrakis","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"coi200076r10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ctrv.2015.05.010","article-title":"Cancer of unknown primary origin in the genomic era: elucidating the dark box of cancer.","volume":"41","author":"Economopoulou","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"coi200076r11","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi200076r12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ctrv.2008.10.003","article-title":"Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.","volume":"35","author":"Pentheroudakis","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"coi200076r13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1476-4598-12-57","article-title":"Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary.","volume":"12","author":"Pentheroudakis","year":"2013","journal-title":"Mol Cancer"},{"issue":"15","key":"coi200076r14","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-12-3030","article-title":"New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.","volume":"19","author":"Varadhachary","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"coi200076r15","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1158\/1078-0432.CCR-10-2599","article-title":"Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.","volume":"17","author":"Varadhachary","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi200076r16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi200076r17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site.","volume":"37","author":"Hayashi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi200076r18","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1093\/annonc\/mdv475","article-title":"Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.","volume":"26","author":"Takeda","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"coi200076r19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2013.92","article-title":"ACMG clinical laboratory standards for next-generation sequencing.","volume":"15","author":"Rehm","year":"2013","journal-title":"Genet Med"},{"key":"coi200076r20","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"coi200076r21","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1200\/JCO.2002.20.6.1651","article-title":"Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.","volume":"20","author":"Greco","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi200076r22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1634\/theoncologist.9-6-644","article-title":"Carcinoma of unknown primary site: sequential treatment with paclitaxel\/carboplatin\/etoposide and gemcitabine\/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.","volume":"9","author":"Greco","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"coi200076r23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/PPO.0b013e3181c6aa89","article-title":"Paclitaxel\/carboplatin\/etoposide versus gemcitabine\/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.","volume":"16","author":"Hainsworth","year":"2010","journal-title":"Cancer J"},{"issue":"10","key":"coi200076r24","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/cncr.v121.10","article-title":"Paclitaxel\/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: a randomized, phase 2 trial.","volume":"121","author":"Hainsworth","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"coi200076r25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies.","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol"},{"issue":"11","key":"coi200076r26","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djt099","article-title":"Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.","volume":"105","author":"Greco","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"coi200076r27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jmoldx.2011.04.004","article-title":"Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification.","volume":"13","author":"Erlander","year":"2011","journal-title":"J Mol Diagn"},{"issue":"6","key":"coi200076r28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1634\/theoncologist.2011-0466","article-title":"A second-generation microRNA-based assay for diagnosing tumor tissue origin.","volume":"17","author":"Meiri","year":"2012","journal-title":"Oncologist"},{"issue":"12","key":"coi200076r29","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","article-title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.","volume":"28","author":"Varghese","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"coi200076r30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1).","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"coi200076r31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-018-0789-x","article-title":"KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.","volume":"17","author":"Rom\u00e1n","year":"2018","journal-title":"Mol Cancer"},{"key":"coi200076r32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101974","article-title":"KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?","volume":"84","author":"Nagasaka","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"coi200076r33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cgh.2016.02.008","article-title":"Molecular biomarkers in the personalized treatment of colorectal cancer.","volume":"14","author":"Sinicrope","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"coi200076r34","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations.","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"coi200076r35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s40425-019-0720-z","article-title":"Clinical and immune profiling for cancer of unknown primary site.","volume":"7","author":"Haratani","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2771755\/jamaoncology_hayashi_2020_oi_200076_1606943496.11119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T11:49:46Z","timestamp":1607600986000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2771755"}},"subtitle":["A Nonrandomized Phase 2 Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.4643","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}